Skip to main content
SpringerLink
Log in

Immuncheckpointhemmer und Co.

Aktuelle Immuntherapien des malignen Melanoms

  • Dermatoonkologie
  • Zertizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Durch zielgerichtete Behandlungsoptionen und Immuncheckpointinhibitoren wurde die Prognose von Patienten mit metastasiertemMelanom deutlich verbessert. Dennoch bedarf es weiterer Forschungsbestrebungen. Zurzeit stehen zum Beispiel verschiedene Kombinationen von Checkpointinhibitoren untereinander und mit anderen Substanzen im Fokus der Forscher.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27(1):3–9.

    Article  PubMed  Google Scholar 

  2. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. Adv Exp Med Biol. 2008;624:89–103.

    Article  PubMed  Google Scholar 

  3. Hölzel D, Engel J. Epidemiologie von malignen Erkrankungen zwischen 20 und 30 Jahren 2011. https://www.onkopedia.com/de/wissensdatenbank/ wissensdatenbank/wissensdatenbank/heranwachsende-und-junge- erwachsene-aya-adolescents-and-young-adults/HoelzelAYA.pdf.

  4. Garbe C et al. Diagnosis and treatment of melanoma: European consensus- based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270–83.

    Article  PubMed  Google Scholar 

  5. Green AC et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30(13):1462–7.

    Article  PubMed  Google Scholar 

  6. Davies H et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  7. Eigentler TK et al. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 3.0-April 2018; AWMF-Register-Nummer: 032/024OL; http://www.awmf.org/uploads/tx_szleitlinien/032- 024OL_l_S3_Melanom-Diagnostik-Therapie-Nachsorge_2018-05.pdf

  8. Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603–15.

    Article  CAS  PubMed  Google Scholar 

  9. Gooden MJ et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yazdi AS et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol. 2006;126(2):393–8.

    Article  CAS  PubMed  Google Scholar 

  11. Schwartzentruber DJ et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.

  12. Rosenberg SA et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Thurner B et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190(11):1669–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17(2):117–27.

    Article  PubMed  Google Scholar 

  15. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  16. Stronen E et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337–41.

    Article  CAS  PubMed  Google Scholar 

  17. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26(32):5275–83.

    Article  CAS  PubMed  Google Scholar 

  18. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.

    Article  CAS  PubMed  Google Scholar 

  20. Topalian SL et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Taube JM et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ribas A et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016;315(15):1600–9.

    Article  CAS  PubMed  Google Scholar 

  23. Ribas A et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.

    Article  CAS  PubMed  Google Scholar 

  24. Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62.

    Article  CAS  PubMed  Google Scholar 

  25. Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.

    Article  CAS  PubMed  Google Scholar 

  26. Weber JS et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol.2015;16(4):375–84.

    Article  CAS  PubMed  Google Scholar 

  27. Höller C, Nguyen V. Nivolumab beim fortgeschrittenen, nicht-resezierbaren oder metastasierten Melanom. J Med Drug Rev. 2016;6:11–22.

    Google Scholar 

  28. Hodi FS et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dummer R et al. Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. J Clin Oncol. 2018;36(Suppl 5):189.

    Article  Google Scholar 

  30. Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270–1.

    Article  PubMed  Google Scholar 

  31. Ribas A et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Ann Oncol. 2017;28(Suppl 5):Abstr 1216O.

    Google Scholar 

  32. Fountzilas C et al. Review: Oncolytic Virotherapy, updates and future directions. Oncotarget. 2017;8(60):102617–39.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Puzanov I et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34(22):2619–26.

    Article  CAS  PubMed  Google Scholar 

  34. Pirard D et al. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology. 2004;208(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  35. Bristol Myers Squibb. Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint 2017. https://news.bms.com/press-release/corporatefinancial-news/phase-3-study-evaluating%C2%A0-safetyand-efficacy-adjuvant-opdivo.

  36. Weide B et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016;22(22):5487–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Spranger S et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5.

    Article  CAS  PubMed  Google Scholar 

  39. Restifo NP et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. D’Urso CM et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991;87(1):284–92.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Sucker A et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res. 2014;20(24):6593–604.

    Article  CAS  PubMed  Google Scholar 

  42. Koyama S et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Katharina Pietschke &  Diana Lomberg

  2. Zentrum für Dermato-Onkologie, Universitäts-Hautklinik Eberhard-Karls-Universität Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Deutschland

    Thomas Kurt Eigentler

Authors
  1. Katharina Pietschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Lomberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Kurt Eigentler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Kurt Eigentler.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Dr. med. Katharina Pietschke und Dr. med. Diana Lomberg erklären, dass keine potenziellen Interessenkonflikte vorliegen. PD Dr. med. Thomas Eigentler gibt Vorträge für MSD Sharp & Dohme, Roche, Bristol-Myers Squibb und Medac an, sowie Adboards für MSD Sharp & Dohme, Bristol-Myers Squibb, Roche und Leo. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pietschke, K., Lomberg, D. & Eigentler, T.K. Aktuelle Immuntherapien des malignen Melanoms. Im Focus Onkologie 21, 44–51 (2018). https://doi.org/10.1007/s15015-018-3604-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3604-z

Search

Navigation